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Abbreviations 
AE  Adverse event 
BP  Blood pressure 
CI  Confidence interval 
ESS  Epworth Sleepiness Scale 
FCM  Ferric carboxymaltose 
FSS  Fatigue Severity Scale 
Hb  Hemoglobin 
IRLS  International Restless Legs Syndrome  
IV  Intravenous 
PLM  Periodic limb movements 
PSQI  Pittsburgh Sleep Quality Index 
RLS  Restless legs syndrome 
SAE  Serious adverse event 
SD  Standard deviation 
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Abstract 
Objective: To test the efficacy and safety of intravenous ferric carboxymaltose (FCM) in 
pregnant women with Restless legs syndrome (RLS) and iron deficiency or anemia. The 
open-label pilot study (exploratory) was performed at the University Hospital of Zürich and  
Neurocenter of Southern Switzerland (Lugano). 
Patient and Methods: Nineteen women in the third trimester of pregnancy with moderate-
to-severe RLS and serum ferritin levels <35 µg/L or hemoglobin (Hb) <11.0 g/dl were 
included in the study. RLS was graded according to the International Restless Legs 
Syndrome (IRLS) Study Group rating scale. All participants had a score of ≥20 or had RLS 
≥3 times/week. Depending on Hb levels, 500 or 700 mg of FCM was administered over 20 
min. The primary endpoint was a ≥50% reduction in the mean IRLS score 1 week after 
FCM infusion. Secondary endpoints included periodic limb movements (PLMs; assessed 
using nocturnal foot actigraphy), sleep quality (assessed using the Pittsburgh Sleep 
Quality Index), and safety. 
Results: The IRLS score decreased from 23 ± 7 (baseline) to 13 ± 7 (P < 0.01), whereas 
the PLM index decreased from 35 ± 26 (baseline) to 25 ± 20 (P < 0.001). Significant 
improvement in sleep quality was also reported (P < 0.029), and treatment was well 
tolerated. Three serious adverse events were reported but were considered unrelated to 
treatment. 
Conclusions: These data provides promising evidence of the safety and efficacy of FCM 
for moderate-to-severe RLS in pregnant women with iron deficiency or anemia. A future 
placebo-controlled study is therefore warranted.  
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Introduction 
Restless legs syndrome (RLS) is characterized by an urge to move the legs; it worsens at 
rest, predominantly in the evening or at night, and is relieved by movement1,2. The majority 
of patients with RLS also present with periodic limb movements (PLMs) during sleep, 
insomnia, and a significant reduction in their quality of life3. 
Pregnancy was first described as a risk factor for RLS by Ekbom4 in 1945. 
Subsequently, several epidemiological studies have confirmed an increased prevalence of 
RLS during pregnancy, with rates of 10%–30% that peak in the third trimester5-8. Notably, 
although the symptoms tend to resolve after delivery, the recurrence rate in subsequent 
pregnancies range from 30% to 60%7, and women who experience RLS during pregnancy 
have a three- to four-fold increased risk of developing idiopathic RLS in later life compared 
with those who had no symptoms during pregnancy. When assessed by the International 
Restless Legs Syndrome (IRLS) Study Group rating scale, severe symptoms have been 
reported in 45% and 54% of pregnant women in two recent studies8,9. Genetic, metabolic, 
and hormonal factors, such as iron deficiency and elevated estradiol levels, have all been 
proposed as determinants of pregnancy-related RLS. However, the current literature 
remains controversial, providing no clear explanation of the underlying mechanisms7,8. 
Pregnancy is the second most important cause of iron deficiency in women after 
menorrhagia. The World Health Organization recommends oral iron supplementation for 
pregnant women with anemia (Hb <10.5 g/dl) and for non-anemic women with iron 
deficiency (ferritin <30 µg/L), while recommending parenteral iron only for women who fail 
to respond to oral iron10. In Switzerland, parenteral ferric carboxymaltose (FCM) is 
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approved for the treatment of iron deficiency and/or anemia from the second trimester of 
pregnancy onward. Moreover, it seems that FCM does not cross the placenta11. 
Recent European guidelines continue to support dopaminergic agents as the first-
line therapy for RLS12. However, dopaminergic agents are not approved for use during 
pregnancy because of their potential to cause fetal malformations, and they are unsuitable 
for use during lactation because they can inhibit prolactin secretion. Alpha-2-delta ligands 
(pregabalin, gabapentin) are also unapproved, although information on their teratogenicity 
is inconclusive. In animal studies, increased indices of fetal structural abnormalities of the 
nervous system have been observed with pregabalin. In addition, Koo et al.133 found 
higher rates for congenital oral malformation with gabapentin therapy. However, in a report 
of 44 live births, gabapentin exposure during pregnancy was not associated with an 
increased risk of adverse fetal events144. However, at present, most first-line therapies 
appear unsuitable for use in pregnancy. 
Iron (FCM) is approved as a category C drug by the Food and Drug Administration 
for use in pregnancy and is indicated as a third-line therapy for RLS and iron deficiency. 
Despite this, there are only limited data and few clinical studies using FCM in pregnant 
women. In an observational study of 65 anemic pregnant women receiving FCM, 20% 
reported minor side effects such as hypotension, headache, nausea, and pruritus, without 
serious adverse events (SAEs)15. However, there have been no well-controlled trials for 
the treatment of pregnancy-related RLS, which remains without an approved treatment 
option16. 
Iron supplementation has been shown to be effective for idiopathic RLS in some 
studies. Although studies with oral dosing are limited, a study by Wang et al.17 
demonstrated significant improvement in patients with low ferritin levels. Of the studies 
using intravenous (IV) iron for RLS, there have been conflicting results18. On the one hand, 
Davis et al.19 did not find any significant improvement with IV therapy. On the other hand, 
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although Ondo et al.20 found IV treatment with iron sucrose to be ineffective, they reported 
that IV treatment with iron dextran led to a significant improvement in severe, refractory 
RLS. In addition, Picchietti et al.21 reported complete remission of RLS symptoms until 5 
months postpartum in a 23-year-old woman treated with IV iron before pregnancy. A case 
report from 2013 also reported two patients who were treated with IV iron sucrose; they 
experienced a significant reduction or remission in RLS symptoms22. 
The objective of this open-label pilot study was to explore the efficacy and safety of 
an iron infusion with FCM during the third trimester of pregnancy in women with RLS and 
iron deficiency. 
 
Methods 
Design and setting 
This was a prospective, uncontrolled, open-label, multicenter pilot study, conducted at the 
Departments of Neurology and Obstetrics, University Hospital of Zurich, and at the Sleep 
Center and Department of Obstetrics, Neurocenter of Southern Switzerland, Civic Hospital 
of Lugano between 2010 and 2013. Participants included in the study received no 
remuneration. Ethical approval was obtained from the Independent Ethics Committees of 
Zurich and Bellinzona, consistent with the principles of the Declaration of Helsinki. The 
clinical trial registration number is NCT01245777. 
 
Participants 
Screening (Visit 1) 
Pregnant women were screened for RLS symptoms over the phone, using the standard 
diagnostic criteria of the International RLS Study Group8. All women with symptoms of 
RLS were interviewed face-to-face by an experienced neurologist to confirm their 
diagnosis. The personal and family histories of RLS, sleep habits, and medical histories 
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were then recorded. Clinical assessments were completed and comprised general and 
neurological examinations, vital signs, body weight, and leg circumference measurements 
to assess leg edema. Blood tests [full blood count, Hb, ferritin, iron, transferrin, C-reactive 
protein (CRP), electrolytes, liver and kidney enzymes, glucose, vitamin B12, folic acid, 
thyroid-stimulating hormone, and estradiol levels] were performed to exclude secondary 
causes of RLS. We used the following standardized questionnaires to evaluate the 
severity of RLS: the IRLS score23, the Fatigue Severity Scale (FSS)24, the Epworth 
Sleepiness Scale (ESS)25, and the Pittsburgh Sleep Quality Index (PSQI)26. 
The inclusion criteria were as follows: met all the essential criteria of the IRLS Study 
Group, in the third trimester of pregnancy; age older than 18 years, moderate-to-severe 
RLS (i.e., an IRLS score ≥20 and/or RLS occurring ≥3 times/per week), and iron deficiency 
(ferritin <35 µg/L) and/or anemia (Hb <11.0 g/dl). 
The exclusion criteria were as follows: age <18 years, current or past (last 3 months before 
treatment) IV iron therapy, twin/multiple pregnancies, severe pre-existing illnesses, 
secondary RLS not due to iron deficiency (e.g., peripheral neuropathy, chronic kidney 
disease, chronic pain syndrome), any disorders of iron metabolism, vitamin B12 or folic 
acid deficiency, significant blood loss (defined as a decrease in Hb levels to <2.0 g/dl), 
pregnancy weight <35 kg, any other pharmacological treatment, and excessive intake of 
alcohol or coffee. All participants gave oral and written informed consent. 
Intervention (Visit 2) 
Each participant received 500 mg of IV FCM approximately 3–6 days after screening. All 
anemic patients with an Hb below 11 g/dl received a second infusion (200 mg IV) 7 days 
after the first infusion. Vital signs were measured at 10-min intervals before, during, and 
after the infusion; the IRLS score was recorded at the end of each infusion. 
Ferinject® contains FCM for i.v. application. One vial with 10 ml solution contains 500 mg 
iron as iron carboxymaltose. Additional ingredients are sodiumhydroxid, hydrochloric acid, 
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H2O. One vial of Ferinject (500mg of FCM) was diluted with 250ml of sterile saline (sterile 
0.9% NaCl) solution. It was administered over a period of 15min i.v. 
 
 
Outcome and follow up (visits 3–8) 
Treatment effects were evaluated using questionnaires (IRLS, FSS, ESS), blood tests (iron, 
ferritin, CRP, estrogen), vital sign measurements, and leg circumference measurements on 
days 3 (visit 3), 7 (visit 4), 14 (visit 5), and 28 (visit 6) after therapy. In addition, the PSQI 
was completed during visits 6 and 8. A telephone interview was conducted 14 days 
postpartum (visit 7) to determine the IRLS score. The final visit (visit 8) was in the obstetrics 
department at 60 days postpartum and included general and neurological examinations, 
vital sign measurements, leg circumference measurements, questionnaire completion, and 
blood tests (Hb, ferritin, CRP, estrogen) . 
Foot actigraphy was performed for three nights before and 7 days after therapy to 
evaluate the evolution of PLM per hour of sleep (i.e., the PLM index), as described by King 
et al.27 When patients required two doses of FCM, the subsequent measurements were 
counted from infusion 1. Treatment responders were defined as patients with ≥50% 
reduction in the mean IRLS score after 14 days. Non-responders were defined as those 
with a <50% reduction in the IRLS score from baseline. 
 
Safety assessment 
Safety data for all patients were included in the analysis. Adverse events (AEs) and SAEs 
were documented by an investigator at each visit, and clinically significant changes in 
clinical assessments and laboratory measurements were recorded. 
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Statistical analysis 
The primary endpoint of this study was a ≥50% reduction in the mean IRLS score from 
baseline at visit 5. The study was not powered but exploratory in design. One-way analysis 
of variance with linear mixed-model analysis was performed. For the primary analysis, a 
two-sided paired t-test with linear mixed-model analysis was performed to assess the 
changes in the ESS, FSS, and PSQI. A P-value of less than 0.05 was considered 
statistically significant. For the secondary analysis, a non-parametric Mann–Whitney U test 
was conducted to detect any reduction in the PLM index from baseline to after therapy. 
Spearman’s rank correlation was used to evaluate the correlation between different 
variables. Baseline differences between responders and non-responders were evaluated 
using Welch two-sample t-tests. The Statistical Package for the Social Sciences (BM 
SPSS Statistics 22; 1989; 2013) was used for all statistical analyses. Descriptive data are 
presented as mean ± standard deviation, unless stated otherwise. 
 
Results 
Participants 
We enrolled 20 pregnant women with moderate-to-severe RLS and iron deficiency 
according to the inclusion/exclusion criteria. One participant discontinued the study before 
receiving any treatment. Overall, 19 women (age, 34 ± 4 years; range, 26–41 years) 
completed the study. 
Before pregnancy, 8/19 (42%) of women reported having already experienced RLS 
unrelated to pregnancy. During pregnancy, none of the patients consumed alcohol; 
however, 16% were smokers (3–7 cigarettes/week), 63% were taking vitamins, and 37% 
were taking magnesium supplements. One patient received a vitamin B12 injection 3 
weeks before screening. Oral iron therapy was stopped 5 days before study inclusion 
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(Table 1). All participants had ferritin levels <35 µg/L and two were anemic (Hb, 10.8 ± 1 
g/dl), requiring a second FCM infusion. 
 
Primary outcome 
The IRLS score decreased from 23 ± 7 (baseline) to 13 ± 7 (P < 0.01) by 7 days after 
treatment. Two weeks after FCM infusion, the IRLS score decreased further to 10 ± 8 
(compared with baseline; 95% confidence interval (CI), 8.21–18.63; P < 0.0005). Ten 
women (52%) were considered responders based on a >50% reduction in the IRLS score 
at visit 5 (14 days after infusion; Fig. 1). Responders reported a mean improvement in the 
IRLS score of 82% (compared with 30% for the nine non-responders). There were no 
significant differences between responders and non-responders with respect to age (P = 
0.49), serum ferritin (P = 0.81), Hb level (P = 0.93), ESS (P = 0.35), FSS (P = 0.88), PSQI 
(P = 0.81), or PLM index (P = 0.43). Four weeks after the FCM infusion, the IRLS score 
was 8 ± 5 (compared to baseline; 95% CI, 9.58–20; P < 0.0005; Fig. 1). Two weeks after 
delivery, the mean IRLS score was 3 ± 4, with seven women (36%) still reporting RLS 
symptoms; of these, four had already suffered from RLS before pregnancy. 
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Secondary outcomes 
The PLM index before treatment was higher than 10 for 14 patients. One week after FCM 
infusion, the PLM index decreased from 35 ± 26 at baseline to 25 ± 20 (95% CI, 2.0–17.4; 
P < 0.001; Fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline serum iron levels were below normal at 18 ± 8 µmol/L, with a transferrin 
saturation of 16% ± 6% and serum transferrin levels of 46 ± 7 µmol/L. Ferritin levels 
increased significantly from 15 ± 8 µg/L to a maximum of 315 ± 119 µg/L by 7 days after 
treatment and declined to 70 ± 27 µg/L by 4 weeks after therapy (Table 2). After treatment, 
the Hb levels increased slowly (but not significantly) over time from 12.0 ± 0.9 g/dl to 12.5 
± 0.8 g/dl. After delivery, the ferritin levels were comparable with those at visit 6. 
Neither daytime sleepiness (ESS) nor fatigue (FSS) showed significant 
improvement, whereas sleep quality according to the PSQI score improved significantly 
from 11 ± 4 to 8 ± 3 (95% CI, 0.25–4.38; P < 0.029; Table 2). There was a significant 
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correlation between sleep quality (PSQI) and the IRLS score (r = 0.77; n = 14/19; P < 
0.002) measured 28 days after therapy. There were no significant correlations between the 
IRLS score and the ESS score, FSS score, Hb levels, ferritin levels, age, weight, or PLM 
index. 
The systolic blood pressure (BP) decreased during the infusion by 8 ± 11 mmHg but 
increased again to 108 ± 14 mmHg 60 min after the infusion. In contrast, the heart rate 
remained stable at 90 ± 13 beats/minute during the infusion. Body weight increased from 
72 ± 10 to 75 ± 11 kg 4 weeks after the FCM infusion. Leg circumference, as assessed 
before therapy and at every visit, did not change significantly over the course of the study. 
 
Adverse advents 
A decrease in the BP by 8 ± 11 mmHg was observed during the infusion in 55% of 
patients. In addition, headache and dizziness (10% of patients) were considered 
medication related. Infections (10% with viral gastroenteritis without sepsis) were not 
considered treatment related. In addition, the nausea and nocturia presented in 26% of 
women were also considered pregnancy related and unrelated to the medication because 
they were present before treatment. There were no reports of local injection site reactions 
or allergic reactions. No extravasation occurred at administration site. The decrease in BP 
could be associated to the infusion rate, although the solution was administered according 
to the swiss agency for therapeutic products (500mg/15min). 
The three following SAEs occurred during the study: one patient suffered from an 
hour-long episode of vaginal bleeding of unknown etiology; one patient was hospitalized 
for 12 h because of periodic uterine contractions in the 38th week of pregnancy; and one 
patient suffered from pre-eclampsia in the 40th week of pregnancy. We determined that 
these events were unrelated to FCM treatment.  
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All AEs resolved before the end of the study. All babies were born healthy, with six 
being delivered before visit 6 (i.e., 4 weeks after the FCM infusion). 
 
Discussion 
RLS occurs in 10%–30% of pregnant women and can have detrimental effects on sleep 
quality and overall wellbeing. Currently, no treatment has been approved for RLS during 
pregnancy. To our knowledge, this pilot study is the first to assess IV iron therapy in 
pregnant women with RLS. Our findings indicate that treatment with FCM is safe and may 
be effective in improving moderate-to-severe RLS in pregnant women with iron deficiency 
or anemia. 
Although the placebo effect is quite high in studies of RLS, two key observations in 
this report suggest that iron infusion had a valid therapeutic effect beyond the placebo 
effect. First, improvement in RLS (mean reduction in the IRLS score of 14 points; 
remission rate, 52%) was similar to the improvement reported during treatment with 
dopamine agonists28,29. Second, PLM, which is an objective marker of RLS, also improved 
significantly, although this was to a lesser extent than that generally observed with 
dopaminergic drugs. However, it is important to note that the effect on PLM may be less 
relevant because some patients with RLS do not experience PLM and because the exact 
relationship between improvement in RLS and PLM is unclear3. Furthermore, the limited 
effect observed on PLM could be due to the large data variance and the fact that 
actigraphy was performed before the full treatment effect on RLS had been achieved. Our 
data are consistent with some reports of improvement in idiopathic RLS and PLM after iron 
infusion30-32. 
Apart from the placebo effect, other factors such as administration route (oral 
versus IV) and the type of iron may play a role in the effectiveness of therapy. Although 
oral iron therapy has been shown to be effective in the treatment of RLS17, ferritin levels 
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increase slowly with oral treatment, leading to a delay in the treatment response by a few 
months33. Bypassing the gastrointestinal–blood barrier with IV iron leads to a more rapid 
increase in ferritin levels and a rapid resolution of symptoms31. Nevertheless, it is not clear 
whether IV iron results in a sustained improvement in RLS for a few months without the 
need for other RLS medications31. 
Concerning the type of iron, studies have demonstrated iron sucrose to be 
ineffective, whereas other studies have reported improvements in idiopathic RLS after iron 
dextran and FCM20,32,34. A possible explanation for the different treatment responses could 
be differences in the pharmacokinetics of the iron formulations. Iron dextran and FCM 
have high molecular weights and high structural homogeneity, whereas iron sucrose 
complexes are semi-robust and release larger amounts of weakly bound iron into the 
blood. These iron complexes are then taken up by macrophages via endocytosis and 
stored as ferritin. A higher concentration and longer bioavailability of iron may therefore 
play a key role in treatment efficacy32. The evidence is less consistent for iron dextran 
between FCM and iron dextran, suggesting that FCM is probably the treatment of choice. 
In this study, the treatment response was not predicted by patient demographics, 
ESS score, FSS score, PLM index, Hb levels, or ferritin levels. The mechanisms leading to 
improvements in RLS after iron infusions during pregnancy remain speculative. We believe 
that iron supplementation exerts a direct effect. In fact, a reduction in brain iron 
concentrations has been reported in patients with idiopathic RLS, even in those with 
normal blood ferritin levels; moreover, this reduction can improve with iron infusions30,35. 
In developed countries, pregnancy represents the second most common cause of 
iron deficiency after menorrhagia. The high demand for iron by the fetus can lead to a 
rapid decline in maternal iron stores and low ferritin levels. For the biological plausibility of 
iron therapy, iron is needed as a cofactor in the synthesis of dopamine36. Hence, 
dopamine synthesis may be reduced if iron levels are low36, which could explain the 
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increase in RLS severity during pregnancy. However, other effects that are related to iron 
infusions, but not directly related to blood iron or ferritin levels, may play a role. This is 
supported by the observation in the present study that the extent and duration of treatment 
response was not strictly linked to blood ferritin levels (Table 2). Furthermore, RLS 
improved after delivery in all patients, including those not responding to iron infusions, as 
reported previously8. After delivery, RLS symptoms were still reported in seven patients 
(36%) but with an average decline in the IRLS score of 53% when compared with the initial 
symptoms. There was no subsequent treatment provided within the protocol. 
Hormonal changes have been suggested to play a role in idiopathic RLS and in 
RLS during pregnancy77,37. In fact, estradiol, prolactin, and progesterone levels increase 
physiologically during pregnancy, reaching their highest levels during the third trimester. 
After delivery, estradiol and progesterone levels decline, while prolactin is released in a 
pulsatile manner. However, in a recent study, we found no differences in estradiol levels 
between patients with and without RLS8. 
In this study, treatment was generally well tolerated, with just two adverse effects 
considered medication related. A decrease in the systolic BP was observed in 10 patients 
during the infusion, and two patients reported dizziness after the infusion. The decrease in 
BP could be associated to the infusion rate, although the solution was administered 
according to the swiss agency for therapeutic products (500mg/15min). Although three 
patients suffered SAEs (vaginal bleeding, pre-eclampsia, and periodic contractions), none 
was considered treatment related and all babies were born healthy. 
In conclusion, the results of the present pilot study are encouraging, thus providing 
evidence to indicate that treatment with FCM is safe and potentially effective for improving 
moderate-to-severe RLS in pregnant women with iron deficiency or anemia. The main 
limitations of this study were the absence of a control group treated with placebo and the 
small sample size. In addition the observed improvement in symptoms the night following 
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the first infusion (with mean reduction in the IRLS score of 10 points) could be due to 
placebo effect.  
 In future studies, actigraphy or polysomnography should be performed for longer 
periods of time and at the time of maximal subjective RLS treatment response.  
However, because the placebo effect is a significant issue in the treatment of RLS, 
the real value of the present investigation is to provide justification for structured, larger 
placebo-controlled trials in the future, which we believe are now warranted. 
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Table and figure legends 
 
 
Figure 1. Decrease in mean International Restless Legs Study Group Rating Scale score 
from baseline over time (mean ± SE). 
Figure 2. Decrease in mean periodic limb movements/hour ± SE before and after treatment 
with ferric carboxymaltose. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Demographic Data 
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Characteristics Mean ± SD  
(N = 19)  
Range and % 
Age, mean, years  34 ± 4 26 – 41 
Weight, mean, Kg 72 ± 10 56 – 92 
High, mean, cm 167 ± 5 158 – 177 
BMIa, mean 26 ± 3 22 – 31 
Pregnancy    
Week of pregnancy  32 ± 3 28 – 37 
Primagravida 10 / 19 52% 
Multigravida  9 / 19 47% 
Prior oral iron treatment  8 / 19 42% 
Vitamins  12 / 19 63% 
Magnesium  7 / 19 36% 
RLS   
RLSb before pregnancy   8 / 19  42% 
RLS in previous pregnancies  4 / 19 21% 
Positive family history for RLS   8 / 19 42% 
Positive family history for RLS and 
 RLS before pregnancy  
 RLS in previous pregnancies 
 
 3 / 19 
 2 / 19 
 
16% 
10.5% 
Prior oral iron treatment and: 
 RLS before pregnancy  
 RLS in previous pregnancies  
 Positive family history 
 
 3 / 19 
 2 / 19  
 3 / 19 
 
16% 
10.5% 
16% 
RLS moderate/RLS occurs >3 times/week 
(IRLSc score, 11–20 points) 
 5 / 19 26% 
RLS severe (21–30) 14 /19 74% 
RLS very severe (31–40)  3 / 19 16% 
a: Body Mass  Index 
 b: Restless Legs Syndrome 
 c: International Restless Legs Syndrome Study Group Rating Scale score 
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Table 2: Secondary outcome 
 
Time (days) 
Screening  
(± 3days) 
Iron 3 d 7 d 14 d 28d 60d 
 
P-Value  
Visit V1 V2 V3 V4 V5 V6 V8 
(Screen 
vs. V5) 
IRLSa   23 ± 7  15 ± 7 13 ± 7 10 ± 8 8 ± 5 5 ± 7 0.001 
Hbb g/dl 
 
12 ± 1 
 
12 ± 1 12 ± 1 12 ± 1 12 ± 1 14 ± 1 1.0 
Ferritin µg/l 15 ± 8 
 413 ± 
128 
315 ± 119 
175 ± 
82 
70 ± 27 72 ± 56 0.001 
Estradiol 
pmol/l 
49362 
 
 
69565 ± 
10792 
  
218 ± 
281 
<0.01 
ESSc 10 ± 5   8 ± 6 7 ± 3 7 ± 3 7 ± 4 0.44 
FSSd 5 ± 1   4 ± 1 4 ± 1 4 ± 2 4 ± 2 0.15 
PSQIe 11 ± 4     8 ± 3 6 ± 4 0.03 
PLMf 35 ± 26   25 ± 20    0.04 
SI conversion factors: To convert Hemoglobin to g/L, multiply values by 10  
a: International Restless Legs Syndrome Study Group Rating Scale score 
b: Hemoglobin 
c: Epworth Sleepiness Scale 
d: Fatigue Severity Scale 
e: Pittsburgh Sleep Quality Index 
f: periodic limb movements 
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